10/518,788

[redacted]

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 7	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 8	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 9	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 10	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 11	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 12	OCT 19	E-mail format enhanced
NEWS 13	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 14	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 15	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 16	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 17	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 18	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 19	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 20	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 21	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 22	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 23	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 24	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 25	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 26	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 27	DEC 18	CA/CAplus patent kind codes updated
NEWS 28	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 29	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 30	DEC 27	CA/CAplus enhanced with more pre-1907 records

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

McIntosh

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:55:33 ON 03 JAN 2007

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:55:50 ON 03 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 JAN 2007  HIGHEST RN 916646-22-5
DICTIONARY FILE UPDATES:   2 JAN 2007  HIGHEST RN 916646-22-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10518788.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 O,NH


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:56:12 FILE 'REGISTRY'
```

11/294,932

SAMPLE SCREEN SEARCH COMPLETED - 19 TO ITERATE

100.0% PROCESSED 19 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 119 TO 641
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:56:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 412 TO ITERATE

100.0% PROCESSED 412 ITERATIONS 195 ANSWERS
SEARCH TIME: 00.00.01

L3 195 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY 172.10 TOTAL SESSION 172.31
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:56:36 ON 03 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Jan 2007 VOL 146 ISS 2
FILE LAST UPDATED: 2 Jan 2007 (20070102/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 11 L3

=> d bib abs 1-11 l4

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1278776 CAPLUS
TI Preparation of A crystals of 2'-(4'-ethylbenzyl)phenyl 5-thio-β-D-glucopyranoside
IN Sato, Masakazu; Kakinuma, Hiroyuki; Asanuma, Hajime; Amada, Hideaki; Shinohara, Toshie
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 13pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006328055	A	20061207	JP 2006-120527	20060425
PRAI JP 2005-130453	A	20050427		

AB Title compound (I) having (a) peaks at 2θ = 7.3, 13.2, 19.2, and 21.8° by the powder x-ray diffraction X (Cu-Kα), (b) IR absorption peaks at 1492, 1238, 832, and 742 cm-1, and/or (c) DSC exothermic peak at 117-123° and endothermic peak at 157-163°

McIntosh

is prepared by (i) dissolving I in organic solvent-water mixture, crystallization at 5-40°, and drying the resulting crystals at 0-65°, or by (ii) suspending I in water (and organic solvent), retaining at 5-30°, and drying the crystals at 0-65°. Thus, I was dissolved in 1:1 EtOH-water mixture at 80°, treated with water, filtered, and dried at 50° in vacuo to give A crystals, which showed good stability at room temperature 75% RH for 4 wk.

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1278775 CAPLUS
TI Preparation of C crystals of 2'-(4'-ethylbenzyl)phenyl 5-thio-β-D-glucopyranoside
IN Koizumi, Narumi; Shinohara, Toshie
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 12pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006328054	A	20061207	JP 2006-120515	20060425
PRAI JP 2005-130454	A	20050427		

AB Title compound (I) having (a) peaks at 2θ = 8.1, 12.8, 19.6, and 23.4° by the powder x-ray diffraction X (Cu-Kα), (b) IR absorption peaks at 1490, 1233, 840, and 745 cm-1, (c) DSC endothermic peak at 157-163°, and/or (d) m.p. 157°-163° is prepared by dissolving I in organic solvent-water mixture, crystallization, and drying the crystals at ≥65°. Thus, I was dissolved in aqueous EtOH, cooled, filtered, and dried at 140° for 3 h to give C crystals, which showed good stability in a sealed container at 40° for 1 mo and higher water solubility than B' crystals.

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1001014 CAPLUS
DN 143:279419
TI Inhibitor of sodium-dependent glucose transporter 2
IN Sato, Masakazu; Kakinuma, Hiroyuki; Asanuma, Hajime
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 70 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2005247834	A	20050915	JP 2005-26180	20050202
PRAI JP 2004-27413	A	20040204		

OS MARPAT 143:279419
GI



I

AB The antidiabetic medicines containing 5-thio-β-D-glucopyranoside compound represented by the following general structure I (p = 0 or 1; Y = -O- or -NH-; R1, R2, R3, R4 could be the same or different and = H, C2-10 acyl, C7-10 aralkyl, and C2-6 alkoxycarbonyl etc.) or pharmaceutically acceptable salts as an active component for the inhibition of sodium-dependent glucose transporter 2 (SGLT2) in the kidney are offered. The application of these compds. in the treatment of diabetes mellitus, its complication and its related diseases is discussed.

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:423742 CAPLUS
DN 142:481875

11/294,932

TI Derivatives of 2-azetidinone as antihypercholesterolemic agents
IN Sings, Heather I.; Ujjainwalla, Feroze; Maccoss, Malcolm; Myers, Robert W.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005044256	A1	20050519	WO 2004-US35845	20041027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004286838	A1	20050519	AU 2004-286838	20041027
CA 2543943	A1	20050519	CA 2004-2543943	20041027
EP 1682117	A1	20060726	EP 2004-796665	20041027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1870988	A	20061129	CN 2004-80031555	20041027
PRAI US 2003-515842P	P	20031030		
WO 2004-US35845	W	20041027		

OS MARPAT 142:481875
GI



I

AB The present invention provides 2-azetidinone derivs., such as I [Ar1, Ar2 = aryl, R4-substituted aryl; X, Y, Z = CH2, CH(C1-6alklyl), C(C1-6alklyl)2; R = OR6, OCOR6, OCO2R6, OCONR6R7, sugar residue; R1 = H, alkyl, aryl; RR1 = oxo; R2 = OR6, OCOR6, OCO2R6, OCONR6R7; R3 = H, alkyl, aryl; R2R3 = oxo; q, r, t = 0 - 1; m, n, p = 0 - 4; R4 = OR6, OCOR6,OCO2R9, OCONR6R7, COR6, CONR6R7, SO2NR6R7, F; R5 = R10-R11, R12-R13, OCF3, NR6R7, F ; R6, R7 = alkyl, aryl, aryl-substituted aryl; R10, R12 = S, SO, SO2, etc.; R11 = sugar, di-sugar, tri-sugar, tetra-sugar residue; R13 = thiasugar, fluoro-sugar; R17 = H, OH, halo, alkyl, O-alkyl, CF3, CN, NR6R7], and the pharmaceutically acceptable salts and esters thereof, for their use as antihypercholesterolemic agents. The 2-azetidinone derivs. I are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:1059367 CAPLUS
DN 142:38476
TI Process for producing aldohexopyranose intermediate
IN Kakinuma, Hiroyuki; Sato, Masakazu; Asanuma, Hajime; Tomisawa, Kazuyuki
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

McIntosh

PI WO 2004106352 A1 20041209 WO 2004-JP7556 20040526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI JP 2003-151753 A 20030529
OS CASREACT 142:38476; MARPAT 142:38476
GI



AB A process for producing a tetra-O-acetylaldohexopyranose represented by the formula (I) (Ac = acetyl; X = O, S; R1 = H, C1-6 alkyl; R2 = C1-6 alkyl, halo-C1-6 alkyl, hydroxy-C1-6 alkyl; or R1 and R2 are bonded to each other and represent, in cooperation with the hydrazine group, optionally substituted N-aminopyrrolidine, N-aminopiperidine, N-aminomorpholine, or N-aminopiperazine, or N-aminoperhydroazepine; R3 = C1-6 alkyl) comprises reacting a penta-O-acetylaldohexopyranose represented by the following formula (II) with a mixture of a hydrazine compound represented by R1R2NNH2 and an organic acid represented by R3COOH to selectively remove an acetyl group at the anomeric position. Thus, to a solution of 42.0 g 1,2,3,4,6-penta-O-acetyl-5-thio-D-glucopyranose in 300 mL DMF was added a mixture of 5.76 g methylhydrazine, 7.50 g AcOH, and 125 mL DMF and the resulting mixture was stirred at room temperature for 2 h, followed by adding an addnl. mixture of 0.967 g methylhydrazine, 1.26 g AcOH, and 21 mL DMF and stirring for addnl. 1 h. The reaction mixture was diluted with 40 mL EtOAc and poured into 400 mL saturated aqueous NaCl, followed by separating the organic layer, successively washing it with 0.5 M aqueous HCl and 400 mL saturated aqueous NaCl, drying over MgSO4, concentration, and purification using silica gel chromatog., 26.5 g 2,3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose (70% yield).
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:872802 CAPLUS
DN 141:366420
TI Method for selective preparation of heteroaryl 5-thio-β-D-aldohexopyranoside by Mitsunobu reaction of heteroaryl alcohols with 5-thio-β-D-aldohexopyranose derivative
IN Kakinuma, Hiroyuki; Sato, Masakazu; Amada, Hideaki; Asanuma, Hajime; Tsuchiya, Yuko
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004089966	A1	20041021	WO 2004-JP1244	20040206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CN 1761676 A 20060419 CN 2004-80007740 20040206
PRAI JP 2003-97838 A 20030401
JP 2003-404959 A 20031203
OS MARPAT 141:366420
GI



I



II



III

AB Disclosed is a method for preparing a heteroaryl 5-thio-β-D-aldohexopyranoside compound of the formula (I) [wherein Y = O, NH; R1-R4 = H, C2-10 aryl, C1-6 alkyl, C7-10 aralkyl, C1-6 alkoxy-C7-10 aralkyl, allyl, tri(C1-6 alkyl)silyl, C1-6 alkoxy-C1-6 alkyl, C2-6 alkoxycarbonyl; or when Y = O, R1 and R2 or R2 and R3 are combined together to form (un)substituted CH2; A = (un)substituted heteroaryl], which comprises reacting 5-thio-D-aldohexopyranose compound of the formula (II) (wherein R1-R4 = same as above) with heteroaryl alc. of formula A-OH (A = same as above) in the presence of a phosphine represented by PRXRYRZ [wherein RX, RY, RZ = C1-6 alkyl, (un)substituted Ph, pyridyl, C1-6 alkyl] and an azo reagent represented by R21-N:N-R22 [wherein R21, R22 = C2-5 alkoxycarbonyl, N,N-di(C1-4 alkyl)aminocarbonyl, piperidinocarbonyl]. Heteroaryl 5-thio-β-D-aldohexopyranosides are useful as inhibitors of sodium-dependent glucose transporter 2 (SGLT2) (no data). Thus, 5.1 mmol di-Et azodicarboxylate (40% toluene solution) was added dropwise to a solution of 2,3,4,6-tetra-O-acetyl-5-thio-D-glucopyranose (937 mg, 2.6 mmol) and 1,2-dihydro-4-(4-ethylbenzyl)-5-methyl-3H-pyrazol-3-one (2.78 g, 12.9 mmol) and PPh3 (1.35 g, 5.1 mmol) in 14 mL THF at room temperature, stirred for at room temperature for 4 h, and concentrated to give, after silica gel chromatog., 20% β-D-thioglucopyranoside compound (III).
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:143171 CAPLUS
DN 140:199631
TI Preparation of aryl 5-thio-β-D-glucopyranoside derivatives as remedies for diabetes
IN Sato, Masakazu; Kakinuma, Hiroyuki; Asanuma, Hajime
PA Taisho Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014931	A1	20040219	WO 2003-JP10160	20030808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,

```
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2478889          A1    20040219    CA 2003-2478889        20030808
    AU 2003254904       A1    20040225    AU 2003-254904         20030808
    BR 2003010006       A     20050215    BR 2003-10006          20030808
    EP 1528066          A1    20050504    EP 2003-784623         20030808
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1639180          A     20050713    CN 2003-805640         20030808
    CN 1675233          A     20050928    CN 2003-819142         20030808
    NZ 535229           A     20060526    NZ 2003-535229         20030808
    JP 3813160          B2    20060823    JP 2004-527383         20030808
    NO 2004003733       A     20041020    NO 2004-3733           20040907
    ZA 2004007187       A     20060222    ZA 2004-7187           20040908
    US 2005209309       A1    20050922    US 2004-518788         20041221
PRAI JP 2002-233015     A     20020809
    JP 2003-97839       A     20030401
    WO 2003-JP10160     W     20030808
OS  MARPAT 140:199631
GI
```



I


```
AB  The title compds. I [Y = O, etc.; R1 - R4 = H, acyl, etc.; Ar = aryl
    having substituents (further details on said substituents are given)] are
    prepared  I are inhibitors of SGL T2 (sodium dependent glucose cotransporter
    2).  In an in vitro test for the inhibition of glucose uptake into brush
    border membrane vesicles of rat kidney, compds. of this invention showed
    IC50 values of 0.16 μM to 2.4 μM.
```


```
RE.CNT  56    THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4  ANSWER 8 OF 11  CAPLUS  COPYRIGHT 2007 ACS on STN
AN  2004:143170  CAPLUS
DN  140:199630
TI  Process for selective production of aryl 5-thio-β-D-
    aldohexopyranosides
IN  Sato, Masakazu; Kakinuma, Hiroyuki; Asanuma, Hajime
PA  Taisho Pharmaceutical Co., Ltd., Japan
SO  PCT Int. Appl., 71 pp.
    CODEN: PIXXD2
DT  Patent
LA  Japanese
FAN.CNT 2
    PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
    --------------      ----   --------    -------------------    --------
PI  WO 2004014930       A1     20040219    WO 2003-JP10159        20030808
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
            TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2493491          A1     20040219    CA 2003-2493491        20030808
    AU 2003254903       A1     20040225    AU 2003-254903         20030808
    EP 1541578          A1     20050615    EP 2003-784622         20030808
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
```

	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
	CN 1639180	A	20050713	CN 2003-805640		20030808
	CN 1675233	A	20050928	CN 2003-819142		20030808
	ZA 2004007187	A	20060222	ZA 2004-7187		20040908
	US 2005256317	A1	20051117	US 2005-521809		20050121
	NO 2005000650	A	20050304	NO 2005-650		20050207
PRAI	JP 2002-233015	A	20020809			
	JP 2003-97839	A	20030401			
	WO 2003-JP10159	W	20030808			

OS MARPAT 140:199630
GI



I



II

10/521,909
this is drawn to methods of making my cpds.
allowed
same priority date

AB This document discloses a process for the production of aryl 5-thio-β-D-aldohexopyranoside derivative I [the wavy line indicates D isomer, L isomer, etc.; Y = O, etc.; R1 - R4 = H, acyl, etc.; Ar = (un)substituted aryl] by reacting a 5-thio-D-aldohexopyranose derivative II [R1 - R4, wavy line = as given above] with ArOH [Ar = as given above] in the presence of a phosphine and an azo reagent.

RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:799909 CAPLUS
DN 132:208052
TI Is There a Generalized Reverse Anomeric Effect? Substituent and Solvent Effects on the Configurational Equilibria of Neutral and Protonated N-Arylglucopyranosylamines and N-Aryl-5-thioglucopyranosylamines
AU Randell, Karla D.; Johnston, Blair D.; Green, David F.; Pinto, B. Mario
CS Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Can.
SO Journal of Organic Chemistry (2000), 65(1), 220-226
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
GI



I

AB The effects of substitution and solvent on the configurational equilibrium of neutral and protonated N-(4-Y-substituted-phenyl) peracetylated 5-thioglucopyranosylamines I (X = S; Y = OMe, H, CF3, NO2) (1-4) and N-(4-Y-substituted-phenyl) peracetylated glucopyranosylamines I (X = O; Y = OMe, H, NO2) (9-11) are described. The configurational equilibrium were determined by direct integration of the resonances of the individual isomers in

the 1H NMR spectra after equilibration of both α- and β-isomers. The equilibrations of the neutral compds. 1-4 in CD3OD, CD3NO2, and (CD3)2CO were achieved by HgCl2 catalysis and those of the neutral compds. 9-11 in CD2Cl2 and CD3OD by triflic acid catalysis. The equilibrations of the protonated compds. in both the sulfur series (solvents, CD3OD, CD3NO2, (CD3)2CO, CDCl3, and CD2Cl2) and oxygen series (solvents, CD2Cl2 and CD3OD) were achieved with triflic acid. The substituent and solvent effects on the equilibrium are discussed in terms of steric and electrostatic effects and orbital interactions associated with the endo-anomeric effect. A generalized reverse anomeric effect does not exist in neutral or protonated N-aryl-5-thioglucopyranosylamines and N-arylglucopyranosylamines. The values of Keq(axial-equatorial) in protonated 1-4 increase in the order OMe < H < CF3 < NO2, in agreement with the dominance of steric effects (due to the counterion) over the endo-anomeric effect. The values of Keq(axial-equatorial) in protonated 9-11 show the trend OMe > H < NO2 that is explained by the balance of the endo-anomeric effect and steric effects in the individual compds.
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:746389 CAPLUS
DN 132:208047
TI Synthesis and glycosidase inhibitory activity of 5-thioglucopyranosylamines. Molecular modeling of complexes with glucoamylase
AU Randell, K. D.; Frandsen, T. P.; Stoffer, B.; Johnson, M. A.; Svensson, B.; Pinto, B. M.
CS Department of Chemistry and Institute of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Can.
SO Carbohydrate Research (1999), 321(3-4), 143-156
CODEN: CRBRAT; ISSN: 0008-6215
PB Elsevier Science Ltd.
DT Journal
LA English
AB The synthesis of a series of 5-thio-d-glucopyranosylarylamines by reaction of 5-thio-d-glucopyranose pentaacetate with the corresponding arylamine and mercuric chloride catalyst is reported. The products were obtained as anomeric mixts. of the tetraacetates which can be separated and crystallized The tetraacetates were deprotected to give α/β mixts. of the parent compds. which were evaluated as inhibitors of the hydrolysis of maltose by glucoamylase G2 (GA). A transferred NOE NMR experiment with an α/β mixture of p-methoxy-N-phenyl-5-thio-d-glucopyranosylamine in the presence of GA showed that only the α isomer is bound by the enzyme. The Ki values, calculated on the basis of specific binding of the α isomers, are 0.47 mM for p-methoxy-N-phenyl-5-thio-d-glucopyranosylamine (I), 0.78 mM for N-phenyl-5-thio-d-glucopyranosylamine (II), 0.27 mM for p-nitro-N-phenyl-5-thio-d-glucopyranosylamine and 0.87 mM for p-trifluoromethyl-N-phenyl-5-thio-d-glucopyranosylamine, and the Km values for the substrates maltose and p-nitrophenyl α-d-glucopyranoside are 1.2 and 3.7 mM, resp. Me 4-amino-4-deoxy-4-N-(5'-thio-α-d-glucopyranosyl)-α-d-glucopyranoside (III) is a competitive inhibitor of GA wild-type (Ki 4 μM) and the active site mutant Trp120 Phe GA (Ki 0.12 mM). Compds. I-III are also competitive inhibitors of α-glucosidase from brewer's yeast, with Ki10 mM, and 0.5 mM, resp. Mol. modeling of the inhibitors in the catalytic site of GA was used to probe the ligand-enzyme complementary interactions and to offer insight into the differences in inhibitory potencies of the ligands.
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:319308 CAPLUS
DN 127:17878
TI Relative nucleophilicity of the two sulfur atoms in 1,5-dithioglucopyranoside
AU Yuasa, Hideya; Kamata, Yujiro; Hashimoto, Hironobu
CS Faculty Bioscience Biotechnology, Tokyo Inst. Technology, Yokohama, 226, Japan
SO Angewandte Chemie, International Edition in English (1997), 36(8), 868-870
CODEN: ACIEAY; ISSN: 0570-0833
PB VCH
DT Journal
LA English
AB Anomeric effect on the regioselective S-oxidation of thioglucopyranoside with

mCPBA is reported.
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib hitstr 9-11 14

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:799909 CAPLUS
DN 132:208052
TI Is There a Generalized Reverse Anomeric Effect? Substituent and Solvent Effects on the Configurational Equilibria of Neutral and Protonated N-Arylglucopyranosylamines and N-Aryl-5-thioglucopyranosylamines
AU Randell, Karla D.; Johnston, Blair D.; Green, David F.; Pinto, B. Mario
CS Department of Chemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Can.
SO Journal of Organic Chemistry (2000), 65(1), 220-226
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
IT 260793-72-4 260793-73-5 260793-74-6
260793-75-7 260793-76-8 260793-77-9
260793-78-0 260793-80-4 260793-89-3
260793-90-6 260793-91-7 260793-92-8
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(substituent and solvent effects on the configurational equilibrium of neutral and protonated N-arylglucopyranosylamines and N-arylthioglucopyranosylamines)
RN 260793-72-4 CAPLUS
CN D-Glucopyranosylamine, N-(4-methoxyphenyl)-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-73-5 CAPLUS
CN D-Glucopyranosylamine, N-phenyl-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-74-6 CAPLUS
CN D-Glucopyranosylamine, 5-thio-N-[4-(trifluoromethyl)phenyl]-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-75-7 CAPLUS
CN D-Glucopyranosylamine, N-(4-nitrophenyl)-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-76-8 CAPLUS
CN D-Glucopyranosylamine, N-(4-methoxyphenyl)-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-77-9 CAPLUS
CN D-Glucopyranosylamine, N-phenyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-78-0 CAPLUS
CN D-Glucopyranosylamine, 5-thio-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-80-4 CAPLUS
CN D-Glucopyranosylamine, N-(4-nitrophenyl)-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260793-89-3 CAPLUS
CN D-Glucopyranosylamine, N-(4-methoxyphenyl)-5-thio-, 2,3,4,6-tetraacetate, trifluoromethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260793-72-4
CMF C21 H27 N O9 S

Absolute stereochemistry.



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



RN 260793-90-6 CAPLUS
CN D-Glucopyranosylamine, N-phenyl-5-thio-, 2,3,4,6-tetraacetate, trifluoromethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260793-73-5
CMF C20 H25 N O8 S

Absolute stereochemistry.



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



RN 260793-91-7 CAPLUS
CN D-Glucopyranosylamine, 5-thio-N-[4-(trifluoromethyl)phenyl]-, 2,3,4,6-tetraacetate, trifluoromethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260793-74-6
CMF C21 H24 F3 N O8 S

Absolute stereochemistry.



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



RN 260793-92-8 CAPLUS
CN D-Glucopyranosylamine, N-(4-nitrophenyl)-5-thio-, 2,3,4,6-tetraacetate, mono(trifluoromethanesulfonate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260793-75-7
CMF C20 H24 N2 O10 S

Absolute stereochemistry.



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:746389 CAPLUS
DN 132:208047
TI Synthesis and glycosidase inhibitory activity of 5-thioglucopyranosylamines. Molecular modeling of complexes with glucoamylase
AU Randell, K. D.; Frandsen, T. P.; Stoffer, B.; Johnson, M. A.; Svensson, B.; Pinto, B. M.
CS Department of Chemistry and Institute of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Can.
SO Carbohydrate Research (1999), 321(3-4), 143-156
CODEN: CRBRAT; ISSN: 0008-6215
PB Elsevier Science Ltd.
DT Journal
LA English
IT 260360-94-9P 260360-95-0P 260360-96-1P
260360-97-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and glycosidase inhibitory activity of thioglucopyranosylamines. mol. modeling of complexes with glucoamylase)
RN 260360-94-9 CAPLUS
CN β-D-Glucopyranosylamine, N-(4-methoxyphenyl)-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-95-0 CAPLUS
CN β-D-Glucopyranosylamine, N-phenyl-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-96-1 CAPLUS
CN β-D-Glucopyranosylamine, N-(4-nitrophenyl)-5-thio- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-97-2 CAPLUS
CN β-D-Glucopyranosylamine, 5-thio-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 260360-86-9P 260360-87-0P 260360-88-1P
260360-89-2P 260360-90-5P 260360-91-6P
260360-92-7P 260360-93-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and glycosidase inhibitory activity of thioglucopyranosylamines. mol. modeling of complexes with glucoamylase)
RN 260360-86-9 CAPLUS
CN α-D-Glucopyranosylamine, N-(4-methoxyphenyl)-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-87-0 CAPLUS
CN β-D-Glucopyranosylamine, N-(4-methoxyphenyl)-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 260360-88-1 CAPLUS
CN α-D-Glucopyranosylamine, N-phenyl-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-89-2 CAPLUS
CN β-D-Glucopyranosylamine, N-phenyl-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 260360-90-5 CAPLUS
CN α-D-Glucopyranosylamine, N-(4-nitrophenyl)-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-91-6 CAPLUS
CN β-D-Glucopyranosylamine, N-(4-nitrophenyl)-5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 260360-92-7 CAPLUS
CN α-D-Glucopyranosylamine, 5-thio-N-[4-(trifluoromethyl)phenyl]-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 260360-93-8 CAPLUS
CN β-D-Glucopyranosylamine, 5-thio-N-[4-(trifluoromethyl)phenyl]-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1997:319308 CAPLUS
DN 127:17878
TI Relative nucleophilicity of the two sulfur atoms in 1,5-dithioglucopyranoside
AU Yuasa, Hideya; Kamata, Yujiro; Hashimoto, Hironobu
CS Faculty Bioscience Biotechnology, Tokyo Inst. Technology, Yokohama, 226, Japan
SO Angewandte Chemie, International Edition in English (1997), 36(8), 868-870
CODEN: ACIEAY; ISSN: 0570-0833
PB VCH
DT Journal
LA English
IT 190649-56-0 190649-57-1 190649-58-2
190649-59-3 190649-60-6 190649-61-7
190649-62-8 190649-63-9 190649-64-0
190649-65-1 190649-66-2 190649-67-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(relative nucleophilicity of the two sulfur atoms in dithioglucopyranoside during regioselective S-oxidation with mCPBA)
RN 190649-56-0 CAPLUS
CN β-D-Glucopyranoside, 4-methoxyphenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-57-1 CAPLUS
CN α-D-Glucopyranoside, 4-methoxyphenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-58-2 CAPLUS
CN β-D-Glucopyranoside, phenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-59-3 CAPLUS
CN α-D-Glucopyranoside, phenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-60-6 CAPLUS
CN β-D-Glucopyranoside, 4-fluorophenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-61-7 CAPLUS
CN α-D-Glucopyranoside, 4-fluorophenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-62-8 CAPLUS
CN β-D-Glucopyranoside, 4-chlorophenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-63-9 CAPLUS
CN α-D-Glucopyranoside, 4-chlorophenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-64-0 CAPLUS
CN β-D-Glucopyranoside, 4-(trifluoromethyl)phenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-65-1 CAPLUS
CN α-D-Glucopyranoside, 4-(trifluoromethyl)phenyl 5-thio-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-66-2 CAPLUS
CN β-D-Glucopyranoside, 4-nitrophenyl 5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-67-3 CAPLUS
CN α-D-Glucopyranoside, 4-nitrophenyl 5-thio-, 2,3,4,6-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 190649-68-4P 190649-69-5P 190649-70-8P
190649-71-9P 190649-72-0P 190649-73-1P
190649-74-2P 190649-75-3P 190649-76-4P
190649-77-5P 190649-78-6P 190649-79-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(relative nucleophilicity of the two sulfur atoms in dithioglucopyranoside during regioselective S-oxidation with mCPBA)
RN 190649-68-4 CAPLUS
CN β-D-Glucopyranoside, 4-methoxyphenyl 5-thio-, 2,3,4,6-tetraacetate,

S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-69-5 CAPLUS
CN α-D-Glucopyranoside, 4-methoxyphenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-70-8 CAPLUS
CN β-D-Glucopyranoside, phenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-71-9 CAPLUS
CN α-D-Glucopyranoside, phenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-72-0 CAPLUS
CN β-D-Glucopyranoside, 4-fluorophenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-73-1 CAPLUS
CN α-D-Glucopyranoside, 4-fluorophenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-74-2 CAPLUS
CN β-D-Glucopyranoside, 4-chlorophenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-75-3 CAPLUS
CN α-D-Glucopyranoside, 4-chlorophenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-76-4 CAPLUS
CN β-D-Glucopyranoside, 4-(trifluoromethyl)phenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-77-5 CAPLUS
CN α-D-Glucopyranoside, 4-(trifluoromethyl)phenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-78-6 CAPLUS
CN β-D-Glucopyranoside, 4-nitrophenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190649-79-7 CAPLUS
CN α-D-Glucopyranoside, 4-nitrophenyl 5-thio-, 2,3,4,6-tetraacetate, S-oxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT